ScoreOncology
Khorana score (chemotherapy-associated VTE)
Estimates the risk of venous thromboembolism in outpatients starting chemotherapy.
Updated 30 October 2026
When to use it
Before starting systemic chemotherapy in an outpatient with cancer, to consider primary thromboprophylaxis.
What it needs
- Primary tumour site
- Pre-chemotherapy platelets ≥ 350 × 10⁹/L
- Haemoglobin < 10 g/dL or use of erythropoiesis-stimulating agents
- Pre-chemotherapy leukocytes > 11 × 10⁹/L
- BMI ≥ 35 kg/m²
The points for each answer and the automatic total are in the app.
How to interpret it
| Result | Interpretation |
|---|---|
| ≤ 0 | Low risk (VTE ≈ 0.3–0.8 %) |
| 1–2 | Intermediate risk (VTE ≈ 1.8–2 %) |
| ≥ 3 | High risk (VTE ≈ 6.7–7.1 %) |
Practical tip
ASCO guidelines suggest offering apixaban, rivaroxaban or LMWH with a score ≥ 2 if bleeding risk is low.
2 more practical tips in the app.
Reference
- Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111(10):4902-4907.
- Key NS, Khorana AA, Kuderer NM, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2020;38(5):496-520.
A support tool for healthcare professionals: it guides and does not replace clinical judgement.
